117 KENDRICK STREET, NEEDHAM, MA
Financial Results, Press Release
Announces Pricing of Public Offering
Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
Investor Presentation
Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
News, Material Contracts
Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload